NABRIVA THERAPEUTICS PLC (NBRV) Forecast, Price Target & Analyst Ratings
NASDAQ:NBRV • IE000OZRGNV6
1.42 USD
0 (0%)
At close: Jul 31, 2023
1.3986 USD
-0.02 (-1.51%)
After Hours: 7/31/2023, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NABRIVA THERAPEUTICS PLC (NBRV).
Forecast Snapshot
Consensus Price Target
$1.02
-28.17% Downside
Next Earnings Forecast
Release DateN/A
PeriodQ2 / 2023
EPS Estimate-$2.35
Revenue Estimate17.748M
ChartMill Buy Consensus
40.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.02
Upside
-28.17%
From current price of $1.42 to mean target of $1.02, Based on 6 analyst forecasts
Low
$1.01
Median
$1.02
High
$1.05
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
40.00%
NBRV was analyzed by 6 analysts. The buy percentage consensus is at 40. So analysts seem to be rather negative about NBRV.
In the previous month the buy percentage consensus was at a similar level.
NBRV was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-09-16 | Northland Capital Markets | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ2 / 2023
EPS Estimate-$2.35
Revenue Estimate17.748M
Revenue Q2Q93.10%
EPS Q2Q47.87%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.03M -46.94% | 28.895M 474.45% | 36.935M 27.82% | 72.189M 95.45% | 105.91M 46.71% | 136.58M 28.96% | 167.1M 22.35% | 191.91M 14.85% | |
| EBITDA YoY % growth | -65.7M 16.93% | -48.172M 26.68% | -50.956M -5.78% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -66.12M 16.82% | -48.528M 26.61% | -51.173M -5.45% | -31.805M 37.85% | -3.655M 88.51% | 15.898M 535.01% | 37.193M 133.95% | 56.563M 52.08% | |
| Operating Margin | -1,314.51% | -167.95% | -138.55% | -44.06% | -3.45% | 11.64% | 22.26% | 29.47% | |
| EPS YoY % growth | -147.75 47.23% | -27.03 81.71% | N/A 34.44% | -8.94 49.57% | -0.96 89.27% | 3.67 482.98% | 8.31 126.39% | 12.26 47.48% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|
| EPS Q2Q % growth | -2.35 47.87% | -1.99 52.76% | -1.36 65.98% |
| Revenue Q2Q % growth | 17.748M 93.10% | 18.768M 105.05% | 22.515M 112.99% |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.185M 21.29% | -7.268M 35.12% | -5.132M 71.51% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
30.20%
EPS Next 5 Year
21.90%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
52.98%
Revenue Next 5 Year
38.14%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NABRIVA THERAPEUTICS PLC / NBRV Forecast FAQ
What is the price target for NBRV stock?
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
Can you provide the consensus estimates for NABRIVA THERAPEUTICS PLC next earnings?
The consensus EPS estimate for the next earnings of NABRIVA THERAPEUTICS PLC (NBRV) is -2.35 USD and the consensus revenue estimate is 17.75M USD.
How many analysts cover NABRIVA THERAPEUTICS PLC (NBRV) stock?
The number of analysts covering NABRIVA THERAPEUTICS PLC (NBRV) is 6.